OSMITROL- mannitol injection, solution

Osmitrol by

Drug Labeling and Warnings

Osmitrol by is a Prescription medication manufactured, distributed, or labeled by Baxter Healthcare Corporation. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    OSMITROL is indicated for:

    • The reduction of intracranial pressure and treatment of cerebral edema;
    • The reduction of elevated intraocular pressure.
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Preparation and Administration Instructions

    • OSMITROL is for intravenous infusion preferably into a large central vein [see Warnings and Precautions (5.5), Description (11)].
    • Prior to administration of OSMITROL, evaluate renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances [see Dosage and Administration (2.2)].
    • Do not administer OSMITROL simultaneously with blood products through the same administration set because of the possibility of pseudoagglutination or hemolysis.

    Preparation

    • 1. Tear overwrap down side at slit and remove solution container.
    • 2. Visually inspect the container. Do not administer unless solution is clear and seal is intact.
      • o If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired.
      • o Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
    • 3. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.
    • 4. Admixing OSMITROL with other medications is not recommended.
    • 5. Inspect OSMITROL visually for particulate matter and discoloration prior to administration. If particulates or discoloration are present, discard the bag.
    • 6. OSMITROL solutions may crystallize when exposed to low temperature. At higher concentrations, the solutions have a greater tendency to crystallize. Inspect OSMITROL for crystals prior to administration. If crystals are visible, re-dissolve by warming the solution up to 70°C, with agitation. Solutions should not be heated in water or in a microwave oven due to potential for product contamination or damage. Allow the solution to cool to room or body temperature before re-inspection for crystals and use.

    Administration

    • 1. Suspend container from eyelet support.
    • 2. Remove protector from outlet port at bottom of container.
    • 3. Attach administration set. Refer to complete directions accompanying set.
    • 4. Use administration sets with a final in-line filter because of the potential for OSMITROL crystals to form.
    • 5. To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.
    • 6. For single use only; discard unused portion.

    2.2 Recommended Dosage

    Prior to administration of OSMITROL, evaluate renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances.

    The total dosage, concentration, and rate of administration depend on the age, weight, and condition of the patient being treated, including fluid requirement, electrolyte balance, serum osmolality, urinary output, and concomitant therapy.

    The following outline of administration and dosage is only a general guide to therapy.

    Reduction of Intracranial Pressure
    Usually a maximum reduction in intracranial pressure can be achieved with a dose of 0.25 gram/kg given intravenously as an intravenous infusion over 30 minutes which may be repeated every six to eight hours.

    During and following OSMITROL infusion, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac and pulmonary function. Discontinue OSMITROL if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5)].

    Reduction of Intraocular Pressure

    The recommended dosage is 1.5 to 2 grams/kg of a 20% w/v solution (7.5 to 10 mL/kg) or as a 15% w/v solution (10 to 13 mL/kg) as a single dose administered intravenously over at least 30 minutes. When used preoperatively, administer OSMITROL sixty to ninety minutes before surgery to achieve maximal reduction of intraocular pressure before operation.

  • 3 DOSAGE FORMS AND STRENGTHS

    OSMITROL Injection:

    • 5% (0.05 grams/mL): 5 grams of mannitol, USP per 100 mL in a single-dose 1000 mL flexible container
    • 10% (0.1 grams/mL): 10 grams of mannitol, USP per 100 mL in a single-dose 500 mL flexible container
    • 15% (0.15 grams/mL): 15 grams of mannitol, USP per 100 mL in a single-dose 500 mL flexible container
    • 20% (0.2 grams/mL): 20 grams of mannitol, USP per 100 mL in single-dose 250 mL and 500 mL flexible containers
  • 4 CONTRAINDICATIONS

    OSMITROL is contraindicated in patients with:

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Serious hypersensitivity reactions, including anaphylaxis, hypotension and dyspnea resulting in cardiac arrest and death have been reported with OSMITROL [see Adverse Reactions (6)].

    Stop the infusion immediately if signs or symptoms of a suspected hypersensitivity reaction develop. Initiate appropriate therapeutic countermeasures as clinically indicated.

    5.2 Renal Complications Including Renal Failure

    Renal complications, including irreversible renal failure have been reported in patients receiving mannitol. Reversible, oliguric acute kidney injury (AKI) has occurred in patients with normal pretreatment renal function who received large intravenous doses of mannitol. Although the osmotic nephrosis associated with mannitol administration is in principle reversible, osmotic nephrosis in general is known to potentially proceed chronic or even end-stage renal failure. Monitor renal function closely, including signs of urine output reduction, during OSMITROL infusion. Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure following administration of OSMITROL. Avoid concomitant administration of nephrotoxic drugs (e.g., aminoglycosides) or, other diuretics with OSMITROL, if possible [see Drug Interactions (7.1, 7.2)].

    Patients with oliguric AKI who subsequently develop anuria while receiving mannitol are at risk of congestive heart failure, pulmonary edema, hypertensive crisis, coma and death.

    During and following OSMITROL infusion for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status. Discontinue OSMITROL if renal function worsens. [see Warnings and Precautions (5.5)].

    5.3 Central Nervous System (CNS) Toxicity

    CNS toxicity manifested by, e.g., confusion, lethargy, coma has been reported in patients treated with mannitol, some resulting in death, in particular in the presence of impaired renal function CNS toxicity may result from high serum mannitol concentrations, serum hyperosmolarity resulting in intracellular dehydration within CNS, hyponatremia or other disturbances of electrolyte and acid/base balance secondary to mannitol administration [see Warnings and Precautions (5.4)].

    At high concentrations, mannitol may cross the blood brain barrier and interfere with the ability of the brain to maintain the pH of the cerebrospinal fluid especially in the presence of acidosis.

    In patients with preexisting compromise of the blood brain barrier, the risk of increasing cerebral edema (general and focal) associated with repeated or continued use of OSMITROL must be individually weighed against the expected benefits.

    A rebound increase of intracranial pressure may occur several hours after the infusion. Patients with a compromised blood brain barrier are at increased risk.

    Concomitant administration of neurotoxic drugs (e.g., aminoglycosides) with OSMITROL may potentiate neurotoxicity. Avoid concomitant use of neurotoxic drugs, if possible [see Drug Interactions (7.3)].

    During and following OSMITROL infusion for the reduction in intracranial pressure, monitor the patient clinically and laboratory tests for changes in fluid and electrolyte status. Discontinue OSMITROL if CNS toxicity develops [see Warnings and Precautions (5.5)].

    5.4 Fluid and Electrolyte Imbalances, Hyperosmolarity

    Depending on dosage and duration, administration of OSMITROL may result in hypervolemia leading to or exacerbating existing congestive heart failure. Accumulation of mannitol due to insufficient renal excretion increases the risk of hypervolemia. Mannitol-induced osmotic diuresis may cause or worsen dehydration/hypovolemia and hemoconcentration. Administration of OSMITROL may also cause hyperosmolarity [see Description (11)].

    Depending on dosage and duration of administration, electrolyte and acid/base imbalances may also result from transcellular shifts in water and electrolytes, osmotic diuresis and/or other mechanisms. Such imbalances may be severe and potentially fatal.

    Imbalances that may result from OSMITROL administration include:

    • Hypernatremia, dehydration and hemoconcentration
    • Hyponatremia, which can lead to headache, nausea, seizures, lethargy, coma, cerebral edema, and death. Acute symptomatic hyponatremic encephalopathy is considered a medical emergency.
    • Hypo/hyperkalemia. The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, agents that may cause QT prolongation, neuromuscular blocking agents) [see Drug Interactions (7.4)].
    • Other electrolyte disturbances
    • Metabolic acidosis/alkalosis

    Pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following OSMITROL administration due to decreased glomerular filtration rate and limited ability to concentrate urine [see Use in Specific Populations (8.4)].

    During and following OSMITROL infusion for the reduction in intracranial pressure, monitor fluid and electrolyte status and discontinue OSMITROL if imbalances occur [see Warnings and Precautions (5.5)].

    5.5 Monitoring/Laboratory Tests

    During and following OSMITROL infusion for the reduction in intracranial pressure, monitor:

    • serum osmolarity, serum electrolytes (including sodium, potassium, calcium and phosphate) and acid base balance,
    • the osmol gap
    • signs of hypo- or hypervolemia, including urine output
    • renal, cardiac and pulmonary function
    • intracranial pressure

    Discontinue OSMITROL if renal, cardiac, or pulmonary status worsens or CNS toxicity develops [see Contraindications (4)].

    5.6 Infusion Site Reactions

    The infusion of hypertonic solutions through a peripheral vein, including OSMITROL at a concentration of 10% w/v or greater, may result in peripheral venous irritation, including phlebitis. Other severe infusion site reactions, such as compartment syndrome and swelling associated with extravasation, can occur with administration of OSMITROL [see Adverse Reactions (6)]. OSMITROL is preferably for administration into a large central vein [see Dosage and Administration (2.1)].

    5.7 Interference with Laboratory Tests

    High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations [see Drug Interactions (7.6)].

    Mannitol may produce false positive results in tests for blood ethylene glycol concentrations [see Drug Interactions (7.6)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions from voluntary reports or clinical studies have been reported with OSMITROL. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    • Hypersensitivity reactions: cardiac arrest, anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, cough, musculoskeletal stiffness, myalgia, urticarial/rash, pruritus, generalized pain, discomfort, nausea, vomiting, and headache. [see Warnings and Precautions (5.1)]
    • Renal Failure: acute kidney injury, osmotic nephrosis, azotemia, anuria, hematuria, oliguria, polyuria [see Warnings and Precautions (5.2)]
    • CNS Toxicity: coma, seizures, confusion, lethargy; rebound increase in intracranial pressure; dizziness [see Warnings and Precautions (5.3)]
    • Fluid and Electrolyte Imbalances: hypovolemia, hypervolemia, peripheral edema, dehydration, hyponatremia, hypernatremia, hyperkalemia, hypokalemia; metabolic acidosis [see Warnings and Precautions (5.4)]
    • Infusion Site Reactions: phlebitis, inflammation, pain, rash, erythema, pruritus; compartment syndrome and swelling associated with extravasation [see Warnings and Precautions (5.6)]
    • Cardiac and Respiratory Disorders: congestive cardiac failure, pulmonary edema, palpitations
    • Gastrointestinal Disorders: thirst, dry mouth
    • General Disorders: asthenia, malaise
  • 7 DRUG INTERACTIONS

    7.1 Nephrotoxic Drugs

    Concomitant administration of nephrotoxic drugs (e.g., cyclosporine, aminoglycosides) increases the risk of renal failure following administration of mannitol. Avoid use of nephrotoxic drugs with OSMITROL, if possible [see Warnings and Precautions (5.2)].

    7.2 Diuretics

    Concomitant administration of other diuretics may potentiate the renal toxicity of mannitol. Avoid use of other diuretics with OSMITROL, if possible [see Warnings and Precautions (5.2)].

    7.3 Neurotoxic Drugs

    Concomitant administration of systemic neurotoxic drugs (e.g., aminoglycosides) with OSMITROL may potentiate the CNS toxicity of mannitol. Avoid use of systemic neurotoxic drugs with OSMITROL, if possible [see Warnings and Precautions (5.3)].

    7.4 Drugs Affected by Electrolyte Imbalances

    The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, drugs that prolong the QT interval, neuromuscular blocking agents) [see Warnings and Precautions (5.4)]. During and following OSMITROL infusion, monitor serum electrolytes and discontinue OSMITROL if cardiac status worsens [see Warnings and Precautions (5.5)].

    7.5 Renally Eliminated Drugs

    Mannitol therapy may increase the elimination, and decrease the effectiveness of treatment with, drugs that undergo significant renal elimination. Concomitant administration of mannitol with lithium may initially increase the elimination of lithium but may also increase the risk of lithium toxicity if patients develop hypovolemia or renal impairment. In patients receiving lithium, consider holding lithium doses during treatment with OSMITROL. In patients requiring concomitant administration of lithium and OSMITROL, frequently monitor serum lithium concentrations and for signs of lithium toxicity.

    7.6 Interference with Laboratory Tests

    High concentrations of mannitol can cause false low results for inorganic phosphorus blood concentrations when an assay based on the conversion of phosphate (orthophosphate) to the phosphomolybdate complex is used.

    Mannitol may produce false positive results in tests for blood ethylene glycol concentrations in which mannitol is initially oxidized to an aldehyde.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see Data). No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of mannitol.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Data

    Human Data

    Published literature reports the presence of mannitol in amniotic fluid when mannitol is administered to pregnant women during the third trimester of pregnancy.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of mannitol in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OSMITROL and any potential adverse effects on the breastfed infant from OSMITROL or from the underlying maternal condition.

    8.4 Pediatric Use

    OSMITROL is approved for use in the pediatric population for the reduction of intracranial and intraocular pressure. Studies have not defined the optimal dose of OSMITROL in the pediatric population. The safety profile for mannitol use in pediatric patients is similar to adults at dosages described in labeling. However, pediatric patients less than two years of age, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following OSMITROL administration due to decreased glomerular filtration rate and limited ability to concentrate urine [see Warnings and Precautions (5.4)].

    8.5 Geriatric Use

    Mannitol is known to be substantially excreted by the kidney and the risk of adverse reactions to this drug may be greater in elderly patients with impaired renal function. Evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of OSMITROL [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5)].

    8.6 Renal Impairment

    Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure with administration of mannitol. Evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of OSMITROL [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5)].

  • 10 OVERDOSAGE

    Signs and symptoms of overdose with OSMITROL include renal failure and AKI, hypo/hypervolemia, hyperosmolarity and electrolyte imbalances, CNS toxicity (e.g., coma, seizures), some of which can be fatal [see Warnings and Precautions (5.2, 5.3, 5.4)].

    Management of overdosage with OSMITROL is symptomatic and supportive. Discontinue the infusion and institute appropriate corrective measures with particular attention to renal, cardiac and pulmonary systems. Correct fluid and electrolyte imbalances.

    OSMITROL is dialyzable (hemodialysis and peritoneal dialysis), hemodialysis may increase OSMITROL elimination.

  • 11 DESCRIPTION

    OSMITROL is a sterile, nonpyrogenic solution of Mannitol, USP in a single-dose flexible container for intravenous administration as an osmotic diuretic. It contains no antimicrobial agents. Mannitol is a six carbon sugar alcohol prepared commercially by the reduction of dextrose. The pH is adjusted with sodium hydroxide or hydrochloric acid. Composition, osmolarity, and pH are shown in .

  • * Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.
    		•

    Table 11

    Size 

    Composition

    *Osmolarity

    pH

    (mL)

    Mannitol, USP
    (g/L)

    (mOsmol/L)
    (calc)

    5%
    OSMITROL

    1000

    50

    274

    5.0
    (4.5 TO 7.0)

    10%
    OSMITROL

    500

    100

    549

    5.0
    (4.5 TO 7.0)

    15%
    OSMITROL

    500

    150

    823

    5.0
    (4.5 TO 7.0)

    20%
    OSMITROL

    250

    200

    1098

    5.0
    (4.5 TO 7.0)

    500
    Osmitrol Injection Structural Formula

    The plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate.

    This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial edema, and intraocular pressure.

    12.3 Pharmacokinetics

    Distribution

    Mannitol distributes largely in the extracellular space in 20 to 40 minutes after intravenous administration. The volume of distribution of mannitol is approximately 17 L in adults.

    Elimination

    In subjects with normal renal function, the total clearance is 87 to 109 mL/min. The elimination half-life of mannitol is 0.5 to 2.5 hours.

    Metabolism

    Only relatively small amount of the dose administered is metabolized after intravenous administration of mannitol to healthy subjects.

    Excretion

    Mannitol is eliminated primarily via the kidneys in unchanged form. Mannitol is filtered by the glomeruli, exhibits less than 10% of tubular reabsorption, and is not secreted by tubular cells. Following intravenous administration, approximately 80% of an administered dose of mannitol is estimated to be excreted in the urine in three hours with lesser amounts thereafter.

    Specific Populations

    Patients with Renal Impairment

    In patients with renal impairment, the elimination half-life of mannitol is prolonged. In a published study, in patients with renal impairment including acute renal failure and end stage renal failure, the elimination half-life of mannitol was estimated at about 36 hours, based on serum osmolarity. In patients with renal impairment on dialysis, the elimination half-life of mannitol was reduced to 6 and 21 hours during hemodialysis and peritoneal dialysis, respectively. [see Use in Specific Populations (8.6), Overdosage (10)].

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    OSMITROL injection is supplied in single-dose, flexible VIAFLEX plastic containers and is available as follows:

    Code

    Size (mL)

    NDC

    Product Name

    2D5604

    1000

    0338-0351-04

    5% (0.05 g/mL mannitol, USP)

    2D5613

    500

    0338-0353-03

    10% (0.1 g/mL mannitol, USP)

    2D5623

    500

    0338-0355-03

    15% (0.15 g/mL mannitol, USP)

    2D5632

    250

    0338-0357-02

    20% (0.2 g/mL mannitol, USP)

    2D5633

    500

    0338-0357-03

    20% (0.2 g/mL mannitol, USP)

    Do not remove container from overwrap until intended for use.

    Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Store at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.

  • 17 PATIENT COUNSELING INFORMATION

    Inform patients or caregivers of the following risks of OSMITROL:

  • SPL UNCLASSIFIED SECTION

    Manufactured by:
    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA

    Printed in USA

    Baxter, Osmitrol, and Viaflex are trademarks of Baxter International Inc.

    07-19-00-1127

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

    Osmitrol Injection Representative Container Label NDC: <a href=/NDC/0338-0351-04>0338-0351-04</a>

    Container Label

    2D5604
    NDC: 0338-0351-04

    5% OSMITROL
    Injection
    (5% Mannitol
    Injection USP)

    1000 mL

    EACH 100 mL CONTAINS 5 g MANNITOL USP pH ADJUSTED WITH
    SODIUM HYDROXIDE OR HYDROCHLORIC ACID pH 5.0 (4.5 TO 7.0)
    OSMOLARITY 274 mOsmol/L (CALC) STERILE NONPYROGENIC
    SINGLE DOSE CONTAINER OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY
    AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE AND
    INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY DISCARD IF
    LEAKS ARE FOUND DO NOT ADMINISTER SIMULTANEOUSLY WITH BLOOD
    MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
    SOLUTION IS CLEAR RX ONLY STORE UNIT IN MOISTURE BARRIER
    OVERWRAP AT ROOM TEMPERATURE (25°C/77ºF) UNTIL READY TO USE
    AVOID EXCESSIVE HEAT SEE INSERT

    VIAFLEX CONTAINER
    PL 146 PLASTIC

    FOR PRODUCT INFORMATION
    1-800-933-0303

    BAXTER OSMITROL VIAFLEX
    AND PL 146 ARE TRADEMARKS OF
    BAXTER INTERNATIONAL INC 

    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA
    MADE IN USA

    Osmitrol Injection Representative Carton Label NDC: <a href=/NDC/0338-0351-04>0338-0351-04</a>

    Carton Label

    2D5604X 14-1000 ML
    VIAFLEX CONTAINER

    5% OSMITROL INJECTION
    5% MANNITOL INJECTION, USP

    EXP
    XXXXX

    SECONDARY BAR CODE
    (17) YYMM00 (10) XXXXX

    LOT
    XXXXX

    PRIMARY BAR CODE
    (01) 50303380351041

    Osmitrol Injection Representative Container Label NDC: <a href=/NDC/0338-053-03>0338-053-03</a>

    Container Label

    2D5613
    NDC: 0338-0353-03

    10% OSMITROL
    Injection
    (10% Mannitol
    Injection USP)

    500 mL

    EACH 100 mL CONTAINS 10 g MANNITOL USP pH
    ADJUSTED WITH SODIUM HYDROXIDE OR HYDROCHLORIC ACID
    pH 5.0 (4.5 TO 7.0) HYPERTONIC OSMOLARITY 549
    mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE
    CONTAINER OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY
    AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS
    SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
    STERILITY DISCARD IF LEAKS ARE FOUND DO NOT
    ADMINISTER SIMULTANEOUSLY WITH BLOOD MUST NOT BE
    USED IN SERIES CONNECTIONS DO NOT USE UNLESS
    SOLUTION IS CLEAR RX ONLY STORE UNIT IN MOISTURE
    BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77ºF)
    UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT

    VIAFLEX CONTAINER
    PL 146 PLASTIC

    FOR PRODUCT INFORMATION
    1-800-933-0303

    BAXTER OSMITROL VIAFLEX
    AND PL 146 ARE TRADEMARKS OF
    BAXTER INTERNATIONAL INC 

    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA
    MADE IN USA

    Osmitrol Injection Representative Carton Label NDC: <a href=/NDC/0338-0353-03>0338-0353-03</a>

    Carton Label

    2D5613Q 24-500 ML

    VIAFLEX CONTAINER

    10% OSMITTROL INJECTION
    10% OSMITROL INJECTION, USP

    EXP
    XXXXX

    SECONDARY BAR CODE
    (17) YYMM00 (10) XXXXX

    LOT
    XXXXX

    PRIMARY BAR CODE
    (01) 50303380353038

    Osmitrol Injection Representative Container Label NDC: <a href=/NDC/0338-0355-03>0338-0355-03</a>

    Container Label

    2D5623
    NDC: 0338-0355-03

    15% OSMITROL
    Injection
    (15% Mannitol
    Injection USP)

    500 mL

    EACH 100 mL CONTAINS 15 g MANNITOL USP pH ADJUSTED WITH
    SODIUM HYDROXIDE OR HYDROCHLORIC ACID pH 5.0 (4.5 TO 7.0)
    OSMOLARITY 823 mOsmol/L (CALC) HYPERTONIC MAY CAUSE
    VEIN DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINER
    OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY AS DIRECTED BY A
    PHYSICIAN USING A FILTER TYPE SET SEE DIRECTIONS CAUTIONS
    SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY
    DISCARD IF LEAKS ARE FOUND DO NOT ADMINISTER SIMULTANEOUSLY
    WITH BLOOD MUST NOT BE USED IN SERIES CONNECTIONS DO NOT
    USE UNLESS SOLUTION IS CLEAR IF CRYSTALS ARE VISIBLE REDISSOLVE
    BY WARMING UNIT TO 70°C/158°F WITH AGITATION COOL TO ROOM
    TEMPERATURE AND REINSPECT FOR CRYSTALS BEFORE INFUSION
    RX ONLY     STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM
    TEMPERATURE (25°C/77ºF) UNTIL READY TO USE AVOID EXCESSIVE
    HEAT SEE INSERT

    VIAFLEX CONTAINER
    PL 146 PLASTIC

    FOR PRODUCT INFORMATION
    1-800-933-0303

    BAXTER OSMITROL VIAFLEX
    AND PL 146 ARE TRADEMARKS OF
    BAXTER INTERNATIONAL INC 

    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA
    MADE IN USA

    Osmitrol Injection Representative Carton Label NDC: <a href=/NDC/0338-0355-03>0338-0355-03</a>

    Carton Label

    2D5623Q 24-500 ML
    VIAFLEX CONTAINER

    15% OSMITROL INJECTION
    15% OSMITROL INJECTION, USP

    EXP
    XXXXX

    SECONDARY BAR CODE
    (17) YYMM00 (10) XXXXX

    LOT
    XXXXX

    PRIMARY BAR CODE
    (01) 50303380355032

    Osmitrol Injection Representative Container Label NDC: <a href=/NDC/0338-0357-02>0338-0357-02</a>

    Container Label

    LOT EXP

    2D5632
    NDC: 0338-0357-02

    20% OSMITROL Injection
    (20% Mannitol Injection USP)

    250 mL EACH 100 mL CONTAINS
    20 g MANNITOL USP
    pH ADJUSTED WITH SODIUM HYDROXIDE OR
    HYDROCHLORIC ACID pH 5.0 (4.5 TO 7.0)
    OSMOLARITY 1098 mOsmol/L (CALC)
    HYPERTONIC MAY CAUSE VEIN DAMAGE
    STERILE NONPYROGENIC SINGLE DOSE
    CONTAINER OSMOTIC DIURETIC DOSAGE
    INTRAVENOUSLY AS DIRECTED BY A
    PHYSICIAN USING A FILTER TYPE SET SEE
    DIRECTIONS CAUTIONS SQUEEZE AND
    INSPECT INNER BAG WHICH MAINTAINS
    PRODUCT STERILITY DISCARD IF LEAKS ARE
    FOUND DO NOT ADMINISTER
    SIMULTANEOUSLY WITH BLOOD MUST NOT BE
    USED IN SERIES CONNECTIONS DO NOT USE
    UNLESS SOLUTION IS CLEAR IF
    CRYSTALS ARE VISIBLE REDISSOLVE BY
    WARMING UNIT TO 70°C/158°F WITH
    AGITATION COOL TO ROOM TEMPERATURE
    AND REINSPECT FOR CRYSTALS BEFORE
    INFUSION RX ONLY STORE UNIT IN
    MOISTURE BARRIER OVERWRAP AT ROOM
    TEMPERATURE (25°C/77ºF) UNTIL READY TO
    USE AVOID EXCESSIVE HEAT SEE INSERT

    VIAFLEX CONTAINER PL 146 PLASTIC

    FOR PRODUCT INFORMATION
    1-800-933-0303

    BAXTER OSMITROL VIAFLEX
    AND PL 146 ARE TRADEMARKS OF
    BAXTER INTERNATIONAL INC 

    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA
    MADE IN USA

    Osmitrol Injection Representative Carton Label NDC: <a href=/NDC/0338-0357-02>0338-0357-02</a>

    Carton Label

    2D5623Q 36-500 ML
    VIAFLEX CONTAINER

    20% OSMITROL INJECTION
    20% OSMITROL INJECTION, USP

    EXP
    XXXXX

    SECONDARY BAR CODE
    (17) YYMM00 (10) XXXXX

    LOT
    XXXXX

    PRIMARY BAR CODE
    (01) 50303380357029

  • INGREDIENTS AND APPEARANCE
    OSMITROL 
    mannitol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0338-0351
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    MANNITOL (UNII: 3OWL53L36A) (MANNITOL - UNII:3OWL53L36A) MANNITOL5 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0338-0351-041000 mL in 1 BAG; Type 0: Not a Combination Product06/08/1964
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01368406/08/1964
    OSMITROL 
    mannitol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0338-0353
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    MANNITOL (UNII: 3OWL53L36A) (MANNITOL - UNII:3OWL53L36A) MANNITOL10 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0338-0353-03500 mL in 1 BAG; Type 0: Not a Combination Product06/08/1964
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01368406/08/1964
    OSMITROL 
    mannitol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0338-0355
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    MANNITOL (UNII: 3OWL53L36A) (MANNITOL - UNII:3OWL53L36A) MANNITOL15 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0338-0355-03500 mL in 1 BAG; Type 0: Not a Combination Product06/08/1964
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01368406/08/1964
    OSMITROL 
    mannitol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0338-0357
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    MANNITOL (UNII: 3OWL53L36A) (MANNITOL - UNII:3OWL53L36A) MANNITOL20 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0338-0357-02250 mL in 1 BAG; Type 0: Not a Combination Product06/08/1964
    2NDC: 0338-0357-03500 mL in 1 BAG; Type 0: Not a Combination Product06/08/1964
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01368406/08/1964
    Labeler - Baxter Healthcare Corporation (005083209)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation059140764ANALYSIS(0338-0351, 0338-0353, 0338-0355, 0338-0357) , LABEL(0338-0351, 0338-0353, 0338-0355, 0338-0357) , MANUFACTURE(0338-0351, 0338-0353, 0338-0355, 0338-0357) , PACK(0338-0351, 0338-0353, 0338-0355, 0338-0357) , STERILIZE(0338-0351, 0338-0353, 0338-0355, 0338-0357)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation194684502ANALYSIS(0338-0351, 0338-0353, 0338-0355, 0338-0357)

    • Trademark Results [Osmitrol]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    OSMITROL
    OSMITROL
    72151100 0751544 Live/Registered
    Travenol Laboratories, Inc.
    1962-08-13
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.